Table 2. Comparison of genetic alterations between patients with h-MDS and NH-MDS.
| Variables | Number examined | Total cohort (%) | h-MDS (%) | NH-MDS (%) | P value |
|---|---|---|---|---|---|
| Mutated | Mutated | Mutated | |||
| FLT3/ ITD | 366 | 1.1% | 1.0% | 1.1% | >0.999 |
| NRAS | 369 | 2.2% | 1.0% | 2.6% | 0.688 |
| KRAS | 367 | 1.1% | 0% | 1.5% | 0.578 |
| JAK2 | 368 | 0.8% | 1.0% | 0.7% | >0.999 |
| RUNX1 | 367 | 11.4% | 4.0% | 14.2% | 0.005* |
| MLL/ PTD | 352 | 0.6% | 0% | 0.8% | >0.999 |
| IDH1 | 368 | 0.5% | 1.0% | 0.4% | 0.470 |
| IDH2 | 366 | 2.2% | 0% | 3.0% | 0.113 |
| ASXL1 | 366 | 17.8% | 7.1% | 21.7% | 0.001* |
| TET2 | 282 | 12.4% | 11.4% | 12.7% | >0.999 |
| DNMT3A | 369 | 10.0% | 3.0% | 12.6% | 0.006* |
| TP53 | 369 | 8.7% | 3.0% | 10.8% | 0.020* |
| SETBP1 | 369 | 2.4% | 1.0% | 3.0% | 0.454 |
| EZH2 | 369 | 3.8% | 0% | 5.2% | 0.014* |
| SF3B1 | 369 | 11.4% | 12.0% | 11.2% | 0.854 |
| U2AF1 | 369 | 7.9% | 5.0% | 8.9% | 0.278 |
| SRSF2 | 369 | 10.8% | 6.0% | 12.6% | 0.089 |
*
Statistically significant if P<0.05.